Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

MLA

Cortes, J., et al. Ponatinib Efficacy and Safety in Philadelphia Chromosome–positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308927321&authtype=sso&custid=ns315887.

APA

Cortes, J., Kim, D., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F., Apperley, J., Khoury, H., Talpaz, M., Deangelo, D., Abruzzese, E., Rea, D., Baccarani, M., Müller, M., Gambacorti-Passerini, C., Lustgarten, S., Rivera, V., Haluska, F., … Kantarjian, H. M. (2018). Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial.

Chicago

Cortes, J, D Kim, J Pinilla-Ibarz, P le Coutre, R Paquette, C Chuah, F Nicolini, et al. 2018. “Ponatinib Efficacy and Safety in Philadelphia Chromosome–positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308927321&authtype=sso&custid=ns315887.